Technology | Ablation Systems | August 15, 2016

FDA Clears Latest Generation Irrigated Ablation Catheter With Force Sensing Technology

Thermocool Smarttouch SF Catheter is the only device to combine contact force technology with a porous tip designed to optimize efficiency in atrial fibrillation ablations

 

Biosense Webster, Smarttouch SF, ablation catheter, AF, Afib, Atrial fibrillation treatment

August 15, 2016 — The U.S. Food and Drug Administration has granted market approval for the Biosense Webster Thermocool Smarttouch SF Catheter. The catheter is the only approved device pairing contact force technology with a porous tip irrigation designed to optimize efficiency. This optimizes efficiency by providing uniform cooling at half the flow rate of earlier generation irrigated catheters, easing the fluid management process. The electrophysiology (EP) device is designed to treat patients with Atrial fibrillation (Afib).

"The Thermocool Smarttouch SF Catheter is an exciting development for patients and electrophysiologists alike, addressing many of the challenges faced using earlier technologies," said Larry A. Chinitz, M.D., professor of medicine and cardiac electrophysiology and clinical director of the Leon Charney Division of Cardiology at the New York University School of Medicine. "With its combination of contact force technology and porous tip design, the device integrates two important features in a way that will help physicians like myself improve outcomes for patients being treated with catheter ablation."

Clinical data has demonstrated the safety of the device when used to treat drug refractory paroxysmal atrial fibrillation. The SMART-AF trial, a multicenter, prospective study of the earlier generation Thermocool Smarttouch technology, revealed no unanticipated adverse events and demonstrated a success rate of greater than 80 percent, with increased stability within the contact force range.[1] Success is defined as freedom from any atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) 12 months post procedure when operator remained in the preset contact force range. 

Further sub-analysis showed that when the contact force was within investigator-selected range ≥ 85% of time, success was increased by 21% to 88% (≥ 85%: n = 32; < 85%: n = 73). The more recent SMART-SF study, which tested the newest generation Thermocool Smarttouch SF Catheter, demonstrated excellent safety results as well.[2] The study found an 18.7 percent reduction in overall procedure time and a 14.2 percent reduction in overall ablation time when compared to the SMART-AF study. It also demonstrated a 55.2 percent reduction in total fluoroscopy time, limiting radiation exposure to patients.[3]

"The Thermocool Smarttouch SF Catheter represents a significant advancement for the clinical community," said Dr. Andrea Natale, Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas. "Conducted trials, including the SMART-AF and SMART-SF studies, have shown Biosense Webster technology enables physicians to achieve targeted stability in the defined contact force range, leading to shorter procedure times and enhanced results without compromising safety."

The catheter is seamlessly integrated with the Carto 3 System, which combines contact force technology, 3-D mapping and advanced navigation capabilities to provide active measurement of stable contact force and catheter tip location.

The Thermocool Smarttouch SF Catheter is available for commercial sale in the United States and Europe.

 

Atrial Fibrillation and Contact Force Therapy

Afib is the most prevalent heart rhythm disorder and a leading cause of stroke among people 65 years and older. An estimated 3 million people in the United States and 20 million worldwide are affected by Afib, and its prevalence is projected to increase significantly as the population ages.[4] Afib is a progressive disease and increases in severity and frequency as patients get older. Left untreated, it can lead to heart valve disease, sleep apnea, chronic fatigue, congestive heart failure and stroke. The public health implications of Afib are a growing concern because those with Afib are at an increased risk of morbidity and mortality, as well as a reduced quality of life. It is estimated to be responsible for 88,000 deaths and $16 billion in additional costs to the U.S. healthcare system on an annual basis.[5]

During catheter ablation, doctors insert a therapeutic catheter through a small incision in the groin, where it is then weaved up to the heart through a blood vessel. Once it reaches the left upper chamber of the heart (atrium), radiofrequency energy is delivered to the heart wall to create lesions that block faulty electrical impulses that can cause heart rhythm disorders.

Watch the VIDEO "Current State of Atrial Fibrillation Technologies," an interview with Dr. Hugh Calkins at HRS 2017.

For more information: www.biosensewebster.com

 

 

References:

1. Natale A, et al. "SMART-AF trial." J Am Coll Cardiol. 2014; 64(7): 647-656. Biosense Webster, Inc. Final Clinical Report, October 2014.
1. THERMOCOOL SMARTTOUCH Catheter IFU (M-5276-693/694) 
2. Prospective Safety Assessment of the THERMOCOOL SMARTTOUCH SF Family of Contact Force Sensing Catheters for the Radiofrequency Ablation Treatment of Drug Refractory Symptomatic PAF (Smart-SF). Biosense Webster Inc. Final Clinical Report, January 2016
3. Compared to SMART-AF study.
4. Naccarelli GV, Varker H, Lin J, Schulman KL. "Increasing prevalence of atrial fibrillation and flutter in the United States." Am J Cardiol.2009;104:1534-1539.
5. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. "Estimation of total incremental health care costs in patients with atrial fibrillation in the United States." Circ Cardiovasc Qual Outcomes 2011;4:313–320.

Related Content

Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init